Earnings are a measure of the money a company is making. That is the reason why companies’ earnings growth captivates almost everyone, from the top brass to research analysts.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in their price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-ove ...

Shares of Evolus, Inc. (EOLS) have gained 5% over the past four weeks to close the last trading session at $14.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $23 indicates a potential upside of 63.2%.The mean estimate comprises six short-term price targets with a standard deviation of $3.85. While the lowest estimate of $16 indicates a 13.6% increase from the current price ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses. In additio ...

Product Dependence - Evolus reported significant reliance on the successful commercialization of its only product, Jeuveau, which is critical for generating revenue [15]. - The company relies entirely on the successful commercialization of its only product, Jeuveau, and may not generate sufficient revenue to continue operations if it fails to market and sell this product [2]. - Evolus relies on the Daewoong Agreement for exclusive distribution rights of Jeuveau; any loss of these rights could adversely affect commercialization efforts [15]. - The company relies on the Daewoong Agreement for exclusive distribution rights of Jeuveau, and any loss of these rights would negatively impact commercialization efforts [2]. Financial Performance - The company has incurred substantial losses since inception and anticipates continued losses in the foreseeable future due to its limited operating history and single approved product [15]. - The company has incurred significant losses since inception and anticipates continued losses for the foreseeable future, complicating future viability assessments [2]. - Additional financing may be required to fund future operations, and failure to secure capital could force the company to limit or terminate operations [2]. - The company may require additional financing to support future operations, and failure to secure capital could hinder growth or lead to operational reductions [15]. - The terms of the Settlement Agreement with Medytox will continue to reduce the company's profitability [2]. Regulatory Challenges - Evolus is dependent on Symatese for regulatory approval of the Evolysse™ dermal filler product line in the U.S. and Europe, with potential delays negatively impacting sales [15]. - The company depends on Symatese for regulatory approval of the Evolysse™ dermal filler product line in the U.S. and Europe, with potential negative impacts on sales if approval is delayed or not obtained [2]. - The company is subject to extensive government regulation, which may result in delays or additional expenses in obtaining regulatory approvals for its product candidates [21]. - Intellectual property claims may delay commercialization efforts and disrupt product supply, impacting competitive ability [2]. Market Competition - Evolus faces significant competition in the market, which may impact its ability to maintain market share and expand its product offerings [15]. - Jeuveau faces significant competition, and failure to compete effectively may hinder market share and expansion [2]. Marketing Limitations - The company is limited to marketing Jeuveau for the treatment of glabellar lines, requiring additional regulatory approvals for broader indications, which could be costly [15]. - The company’s ability to market Jeuveau is limited to treating glabellar lines, requiring additional regulatory approvals for expanded indications, which may be costly [2]. - Evolus is focused on increasing its sales and marketing capabilities to enhance the market presence of Jeuveau, which may present management challenges [21]. Impact of COVID-19 - The ongoing COVID-19 pandemic and potential future outbreaks could adversely affect the company's business operations and financial condition [15]. - The company’s operations may be adversely affected by a resurgence of COVID-19 or similar infectious disease outbreaks [2].

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET. Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025. The filler line will be branded Evolysse™ in the US and Estyme® in the UK and Europe. The Evolys ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET The fireside ch ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 15,101 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under Evolus’ 2023 Inducement Incentive Plan, with a grant date and a vesting commencem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus, Inc. (NASDAQ:EOLS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Louise Chen - Cantor Fitzgerald Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Greetings and welcome to the Evolus Second Quarter 2023 Earnings Conference Call. At this time, all pa ...